VISEN Announces Acceptance of a Biologics License Application for Lonapegsomatropin in China

SHANGHAI, March 7, 2024 /PRNewswire/ — VISEN Pharmaceuticals (VISEN), an innovative biopharmaceutical company focused on endocrine diseases, today announced that the Biologics License Application (BLA) for Lonapegsomatropin (TransCon hGH) was accepted by the China National Medical…

March 8, 2024 March 8, 2024

Share This Article

Previous Article Viiision and Impakt IQ Forge a Partnership to Revolutionize Value Chain Insight, Profitability, and Compliance

Next Article Advancing Healthcare Access: Genesis MedTech Teams Up with Silk Road Medical to Serve Patients affected by Carotid Artery Disease in China

VISEN Announces Acceptance of a Biologics License Application for Lonapegsomatropin in China

Leave a Reply Cancel reply

Stay Connected

Latest News

InvestiQuant Makes Donation to iCCARE for Children with Cancer

GoDaddy Inc. Announces Refinancing of Tranche B-6 Loans

Identity and Access Management Market to grow by USD 14.80 billion (2024-2028), driven by rising global data thefts, with AI powering market evolution – Technavio

Enterprise Mobility Management (EMM) Market to grow by USD 75.37 Billion from 2024-2028, driven by BYOD adoption and AI impact on market trends – Technavio

We influence thousands of users, and we are the number one villavicencio news network on the planet.

Follow US

Sign Up for Our Newsletter